Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma.

Translated title of the contribution: Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma.

L. Goff, K. Summers, S. Iqbal, J. Kuhlmann, M. Kunz, T. Louton, A. Hagenbeek, F. Morschhauser, B. Putz, A. Lister, A. Rohatiner

Research output: Contribution to journalArticleAcademicpeer-review

Translated title of the contributionQuantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma.
Original languageUndefined/Unknown
Pages (from-to)6094-6100
Number of pages7
JournalJournal of Clinical Oncology
Volume27
Issue number36
Publication statusPublished - 2009

Cite this